Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nuvo/Mallinckrodt’s Pennsaid Setback Starts Clock On Generic Launch

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With Nuvo’s new Pennsaid 2% formulation hung up at FDA, Apotex may be able to launch its generic of the old 1.5% formulation of the topical diclofenac product on April 1, 2014, under a settlement announced in January.


Related Content

Nuvo/Galderma Face More Manufacturing Woes Over Topical Anesthetic
Covidien Pure-Play: Pharma Spin-Off Now Officially In The Works
Nuvo's Pennsaid “Approvable” For Osteoarthritis


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts